Filing Flows › Prelude Therapeutics (PRLD) › Stock forecast & fair value
Prelude Therapeutics (PRLD) stock forecast and price target
Prelude Therapeutics (PRLD) trades at $3.60. 5 analysts' median price target is $10.00 (+178%), from $6.00 to $12.00.
Prelude Therapeutics' latest quarter
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PRLD stock?
The median of 5 analysts' 12-month targets is $10.00, +178% from $3.60; the range is $6.00 to $12.00. The average rating is none.
Does Prelude Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is PRLD stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.